Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NanoGBM-Precision in persistent glioblastoma
2021-003774-32Phase 2Terminated
- Sponsor
- University of Rome Tor Vergata, Department of Biomedicine and Prevention
- Start
- Sep 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AGuIX in glioblastoma (GBM), sponsored by University of Rome Tor Vergata, Department of Biomedicine and Prevention. Primary endpoint: Overall response rate. Started Sep 2021; status: terminated.
02
Drugs
AGuIX
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2021-003774-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003774-32.